Athera Biotechnologies AB

February 07, 2012 06:07 ET

Study Linking Outcome in Acute Coronary Syndromes to Anti-PC Published in International Journal of Cardiology

SOLNA, SWEDEN--(Marketwire - Feb 7, 2012) -

Scientists conclude that measuring antibodies to phosporylcholine (anti-PC), using a simple blood-test, may provide important and independent information on the prognosis of heart attack patients, in a study just published on-line in International Journal of Cardiology. The testing was performed using Athera Biotechnologies CVDefine® kit.

Already published studies have reported that low levels of anti-PC in healthy individuals are linked to development of atherosclerosis and serious cardiovascular consequences like heart attack and stroke. This study measured anti-PC levels in samples from 1185 acute coronary syndrome (ACS) patients and shows for the first time that low anti-PC levels indicate poor prognosis in these patients, with a high risk for new cardiovascular events and even death. The scientists suggest that low levels of anti-PC might give an insufficient protection to counteract vascular inflammation and the risk of plaque rupture. Low anti-PC levels may therefore represent a new paradigm for reporting reduced atheroprotection in heart disease and identify patients in need of more intense treatment to prevent secondary events.

"We are in active development of an anti-inflammatory antibody therapy for prevention of secondary cardiovascular events in myocardial infarction patients with low levels of anti-PC. These new findings strengthens the therapeutic approach with a companion diagnostics potential and suggests that increasing anti-PC levels in these patients could have a beneficial effect on outcomes", says Carina Schmidt, CEO of Athera

About Athera Biotechnologies AB (publ)

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

PC-mAb from Athera is in late pre-clinical development, using a unique fully human monoclonal antibody. PC-mAb is being developed to restore cardio- protective levels of anti-PC and prevent secondary CVD events after acute coronary syndrome.

In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera's novel therapeutics.

Athera, a Swedish company, is part of the Karolinska Development AB (publ) portfolio.

News Release as PDF:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Athera Biotechnologies AB via Thomson Reuters ONE


Contact Information

  • For further Information:

    Athera Biotechnologies AB (publ)
    Chief Executive Officer
    Carina Schmidt
    Tel +46 761938190
    Email Contact